+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective

Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective

Molecules 20(4): 6068-6092

Asia has the largest population of any continent and the highest incidence of gastric cancer in the world, making it very important in the context of Helicobacter pylori infection. According to current guidelines, standard triple therapy containing a proton pump inhibitor (PPI) and two antibiotics; amoxicillin (AMX) and clarithromycin (CAM) or metronidazole (MNZ), is still the preferred first-line regimen for treatment of H. pylori infection. However, the efficacy of legacy triple regimens has been seriously challenged, and they are gradually becoming ineffective. Moreover, some regions in Asia show patterns of emerging antimicrobial resistance. More effective regimens including the bismuth and non-bismuth quadruple, sequential, and dual-concomitant (hybrid) regimens are now replacing standard triple therapies as empirical first-line treatments on the basis of the understanding of the local prevalence of H. pylori antimicrobial resistance. Selection of PPI metabolized by the non-enzymatic pathway or minimal first pass metabolism and/or increasing dose of PPI are important to increase H. pylori eradication rates. Therefore, local antibiotic resistance surveillance updates, selection of appropriate first-line regimens with non-enzymatic PPI and/or increased doses of PPI, and detailed evaluation of patients' prior antibiotic usage are all essential information to combat H. pylori antibiotic resistance in Asia.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057226190

Download citation: RISBibTeXText

PMID: 25856059

DOI: 10.3390/molecules20046068

Related references

First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. Alimentary Pharmacology and Therapeutics 21(6): 773-782, 2005

The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Alimentary Pharmacology and Therapeutics 14(7): 893-900, 2000

Levofloxacin in first-line eradication regimens for Helicobacter pylori: better test antibiotic susceptibility before treating. Gut 60(11): 1605; Author Reply 1605-6, 2011

Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Frontiers in Cellular and Infection Microbiology 7: 168, 2017

Sa1910 Time Trends for Helicobacter pylori Eradication Rate of the First-Line and Second-Line Japanese Regimens and Clarithromycin Resistance. Gastroenterology 144(5): S-332, 2013

Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrobial Resistance and Infection Control 8: 40, 2019

M1132 Is There an Association Between Helicobacter pylori Virulence Factor Polymorphisms and Antibiotic Resistance in Asian Patients?. Gastroenterology 138(5): S-338-S-339, 2010

Prevalence of antibiotic resistance of Helicobacter pylori isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regimens. Clinical Microbiology and Infection 8(9): 598-603, 2002

Influence of resistance of Helicobacter pylori to antibiotics on the Helicobacter pylori eradication regimens. Zhonghua Yi Xue Za Zhi 86(38): 2679-2682, 2006

Levofloxacin-based triple regimens were better than standard quadruple regimens for second-line eradication of Helicobacter pylori. Acp Journal Club 141(1): 19, 2004

Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?. Bmc Gastroenterology 17(1): 31, 2017

Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Digestive Diseases and Sciences 59(6): 1235-1243, 2014

Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance. Current Pharmaceutical Design 20(28): 4510-4516, 2014

Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates. Helicobacter 21(5): 382-388, 2016

Twice a day quadruple therapy for the first-line treatment of Helicobacter pylori in an area with a high prevalence of background antibiotic resistance. Acta Gastro-Enterologica Belgica 76(1): 34-37, 2013